Eines meiner Lieblings Start-ups in der Schweiz, Molecular Partners, hat heute eine tolle Ankündigung gemacht:

“…announced a collaborative research and license agreement with Centocor Research & Development, Inc. The collaboration will focus on the development of DARPins to treat inflammatory diseases.

Molecular Partners will receive an upfront payment of $5 million, additional research funding and license fees. Further, Molecular Partners will receive FTE payments for research done under the agreement. Molecular Partners is entitled to receive royalty payments on net sales of any product from this collaboration.”

Damit fliessen schon mal 5 Millionen Dollar in die Kassen. Zudem ist ein potenzieller Blockbuster im Rennen – Bravo und Gratulation an das ganze Team, rund um den sympathischen CEO Christian Zahnd!

Weitere SwissStartups-Posts über Molecular Partners:

#1: Molecular Partners gibt Gas!

#2: Molecular Partners kurz vor dem Trade Sale?

#3: Da hätte ich auch investiert!

This entry was posted on Dienstag, Januar 15th, 2008 at 18:57 and is filed under Startup Success. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.